LY2157299
13665
Phase 2 small_molecule completed
Quick answer
LY2157299 for Carcinoma, Hepatocellular is a Phase 2 program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly and Company
- Indication
- Carcinoma, Hepatocellular
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed